Cytodyn Inc (CYDY)

[Borel Fields]

Jaylimab - conceivable (not likely) to change endpoints. The 7-point ordinal scale is the secondary measure in this study that others are using that has better resolution.

In the other direction, we could have significance in both the primary endpoint and the SOFA (organ failure, clotting driven) secondary measure. That would conclusively support the Patterson's MOA.

Organ failure is a rarer event I think, so more difficult to detect, but given BP's statements about zero clotting, it's possible we could have zero events on this score. That drops the variance!